Why Can’t Females Donate Platelets?

Females can donate platelets, and in most countries they do. The widespread belief that women are categorically barred from platelet donation is a misconception rooted in a real but more specific concern: pregnancy can trigger the immune system to produce antibodies that, when transfused into a patient, raise the risk of a serious lung reaction called transfusion-related acute lung injury, or TRALI. Because of this, many blood services either screen previously pregnant women or preferentially collect platelets from male donors and women who have never been pregnant. The restriction is not about sex itself but about pregnancy history, and the policies vary widely from one blood center to another.

What TRALI Is and Why It Matters

TRALI is a rare but dangerous complication of blood transfusion. Within hours of receiving a transfusion, a patient develops sudden difficulty breathing and fluid buildup in the lungs. Most cases are triggered when antibodies in the donated blood latch onto the recipient’s white blood cells, setting off an inflammatory cascade that damages the tiny blood vessels in the lungs.¹ The antibodies most commonly responsible target proteins called HLA antigens, which sit on the surface of most cells and help the immune system distinguish “self” from “foreign.”

TRALI has been the leading cause of transfusion-associated death in the United States, even after mitigation strategies were introduced.² Platelet products carry a disproportionate share of the risk because they contain a relatively large volume of donor plasma, and plasma is where the antibodies live. That is why platelet donation policies get more scrutiny than, say, red blood cell donation policies.

How Pregnancy Creates the Antibodies

During pregnancy, the fetus carries HLA proteins inherited from the father that the mother’s immune system may not recognize. Her body can mount an immune response against those foreign markers, producing HLA antibodies that persist in her bloodstream long after delivery. This process, called alloimmunization, is essentially the same mechanism behind organ transplant rejection, just triggered by the fetus instead of a transplanted organ.

The more pregnancies a woman has had, the more likely she is to carry these antibodies. In a large U.S. study of nearly 6,000 female donors, about 24% of those with a history of pregnancy tested positive for HLA antibodies. The rate climbed steeply with the number of pregnancies: roughly 11% after one pregnancy, 22% after two, 28% after three, and 32% after four or more.³ By contrast, women who had never been pregnant had an antibody rate of less than 2%, which is essentially on par with male donors. A separate study confirmed that pregnancy is a far more potent driver of HLA alloimmunization than prior blood transfusion, and recommended that TRALI prevention efforts focus specifically on previously pregnant donors.⁴

Data from other populations tells a similar story. A study in India found that HLA antibody rates rose with the number of pregnancies and reached 100% in women with six or more deliveries, though sample sizes at the high end of parity were small.⁵ The pattern is consistent everywhere it has been studied: pregnancy is the dominant risk factor, and more pregnancies mean more risk.

What Blood Services Actually Do

Countries have adopted different strategies to manage this risk, and the differences explain much of the confusion about whether women “can” or “cannot” donate platelets. In 2003, the United Kingdom became the first country to implement a male-predominant plasma policy, essentially discarding the plasma portion of female whole blood donations and preferring male donors for platelet apheresis.⁶ Many other countries followed with their own versions of the policy.

The approaches generally fall into three categories:

Male-only preference: Some centers collect apheresis platelets exclusively or preferentially from male donors and from women who have never been pregnant. This is the simplest approach but has the largest impact on donor availability.
Antibody screening: Other centers allow previously pregnant women to donate but test their blood for HLA antibodies first. Only those who test positive are deferred. This approach preserves more of the donor pool but requires laboratory infrastructure and ongoing retesting after each new pregnancy.⁷
Selective screening: A middle path where only women who report a prior pregnancy are tested, and women who have never been pregnant donate without additional screening. Modeling suggests this approach could reduce TRALI risk by about 60% while preserving much of the female donor pool.⁸

The policies have worked. Over the decade following the introduction of TRALI mitigation strategies, TRALI rates dropped dramatically. One large analysis found that the overall TRALI rate fell from about 2.9 per million transfusions in 2007 to 0.6 per million in 2017. During the earlier period, TRALI rates from female-donated plasma were more than 20 times higher than from male-donated plasma. After mitigation policies took full effect, the gap narrowed considerably, though female-donated apheresis platelets still showed a higher rate than male-donated ones.⁹

Never-Pregnant Women Face Far Fewer Restrictions

This is the point that gets lost in casual conversation about platelet donation rules. A woman who has never been pregnant has essentially the same TRALI risk profile as a male donor. The large U.S. study mentioned earlier found that just 1.7% of never-pregnant women carried HLA antibodies, and prior pregnancy history had a negative predictive value of over 98%, meaning that knowing a woman had never been pregnant was an extremely reliable indicator that she would not have the problematic antibodies.³ At blood centers that use a screening approach rather than a blanket ban, these women are typically welcomed as platelet donors without any additional testing.

Even among previously pregnant women, the majority do not carry antibodies. The roughly 24% positivity rate means that about three out of four women with a pregnancy history could donate safely. Screening identifies those who cannot, rather than excluding an entire demographic. The practical tension is between the cost and logistics of testing versus the simplicity of a blanket policy. Facilities with high-throughput antibody testing platforms tend to favor screening; smaller operations lean toward a male-preference rule because it is cheaper and easier to administer.

The Blood Supply Impact

Blanket policies that exclude all female donors from platelet apheresis carry real costs for the blood supply. A Brazilian analysis estimated that deferring all female donors from apheresis platelet collection would reduce the available pool by about 24%. But deferring only women who had multiple pregnancies would reduce it by just 5%.¹⁰ A U.S. analysis found that a blanket deferral for prior pregnancy or transfusion would eliminate nearly 29% of apheresis platelet donors, but antibody screening at an appropriate threshold could cut that loss to around 8–13%.¹¹

Platelets have a shelf life of only five days, making them the most perishable major blood component. Anything that shrinks the donor pool has an outsized impact on availability. Blood services are constantly balancing recipient safety against the need to maintain an adequate platelet supply, and the trend has been toward more targeted screening rather than broad exclusion of women.

Other Practical Factors for Female Donors

TRALI risk is the headline reason for restrictions, but a few other biological differences affect the platelet donation experience for women, even if they do not amount to outright barriers.

Women tend to have a smaller total blood volume than men. During apheresis, the machine draws blood, separates the platelets, and returns the rest. The temporary drop in circulating blood volume can trigger what is called a vasovagal reaction: dizziness, nausea, or fainting. Studies have found that female sex and smaller total blood volume are associated with a higher rate of these citrate-related and vasovagal reactions during apheresis.¹² One analysis found that while a clear threshold for adverse reactions could be identified in male donors when collection volumes exceeded a certain level, no clean threshold could be identified in female donors, suggesting that the relationship between collection volume and reaction risk is more complex in women.¹³ These reactions are almost always mild and short-lived, but they contribute to a higher deferral rate and can discourage repeat donation.

Iron stores are another consideration. Menstruating women already lose iron monthly, and platelet apheresis, while returning most red blood cells, still involves some loss. Research has shown that menstrual blood loss and whole blood donation are the two most important determinants of ferritin and hemoglobin levels in premenopausal female donors.¹⁴ Women who undergo frequent apheresis procedures at short intervals are prone to iron depletion unless they take supplements.¹⁵ Vein access can also play a role: one analysis of platelet donor deferrals found that the most common reason for deferral across both sexes was inadequate vein access, which disproportionately affected female applicants relative to their smaller numbers.¹⁶

Do Female Platelets Work Differently Once Transfused?

One reasonable worry is whether platelets from female donors, even if they do not trigger TRALI, might perform worse in the recipient’s body. A large study examined platelet recovery and the time to next transfusion in recipients who received platelets from male versus female donors. After adjusting for differences in blood volume, neither donor sex nor recipient sex made any difference in how well the transfused platelets worked.¹⁷ In other words, once the TRALI risk is accounted for, the platelets themselves function the same regardless of the donor’s sex.

There are real biological differences in how platelets behave between men and women. Women tend to have higher platelet counts than men, and their platelets may be slightly more reactive in certain situations.¹⁸ These differences matter for cardiovascular pharmacology but do not translate into meaningful differences in transfusion outcomes. The higher count in women may actually be partially related to lower iron stores, since moderate iron deficiency is known to stimulate platelet production.¹⁹

Reducing the Plasma Content as an Alternative

One technological workaround that sidesteps the antibody issue to some degree is platelet additive solutions, or PAS. These are synthetic solutions that replace most of the donor plasma in the platelet bag, reducing the plasma content by about two-thirds. Since the problematic HLA antibodies travel in the plasma, less plasma means less antibody exposure for the recipient. Almost all modern apheresis devices can perform this substitution automatically.²⁰ The use of PAS has been shown to reduce adverse transfusion reactions overall, though some experts argue that platelets function better in full plasma. In centers that routinely use PAS, the case for excluding female donors becomes weaker, because even if a donor’s plasma contains HLA antibodies, the recipient gets substantially less of it.

How Policies Have Evolved Over Time

The understanding of TRALI has changed rapidly over the past two decades, and policies have shifted accordingly. The UK led the way in 2003 with its male-predominant plasma strategy.⁶ A meta-analysis of ten observational studies confirmed that these low-risk donor strategies were protective, with the greatest benefit seen in critically ill patients and those undergoing high-risk surgeries.²¹

But the strategies have not eliminated TRALI entirely. TRALI can also be triggered by antibodies in male donors (especially those with a history of transfusion), by non-antibody mechanisms, and by factors in the recipient that make the lungs vulnerable. The “two-hit” model of TRALI holds that a predisposing condition in the recipient, such as critical illness or recent surgery, combines with the antibody trigger from the donor to produce the lung injury. This model explains why identical donor products might cause TRALI in one recipient but not another.

The current trajectory in transfusion medicine is toward more nuanced, data-driven approaches. Early screening studies found that deferring all previously pregnant women would sideline about 8% of female platelet donors, but antibody testing could narrow that figure considerably.²² As testing technology has improved and become cheaper, more centers have moved toward screening rather than blanket exclusion. The American Red Cross, for instance, tests female apheresis donors who have been pregnant rather than excluding them outright.

Sex Differences in Platelet Counts

Women consistently have higher circulating platelet counts than men. A study comparing healthy men and women found average counts of about 252 billion per liter in women versus 222 billion per liter in men.²³ Paradoxically, women also had lower levels of thrombopoietin, the hormone that stimulates platelet production, suggesting that the higher counts are not driven by more aggressive bone marrow signaling. The difference may instead reflect the iron-platelet connection described above, where lower iron stores from menstruation drive the body to produce more platelets as a compensatory response.

From a donation standpoint, higher baseline platelet counts are actually an advantage. Apheresis machines typically require donors to have a platelet count above a certain minimum to safely collect a therapeutic dose while leaving the donor with enough platelets for normal clotting. On average, women clear this threshold at least as easily as men. The irony is that the population with higher platelet counts is the one more likely to face donation restrictions, not because of the platelets themselves but because of what may be floating in the surrounding plasma.